Medicare Drug Price Negotiations Are Coming

Earlier this month, the White House announced a major agreement with two pharmaceutical manufacturers to lower the cost of widely used weight-loss drugs and expand Medicare coverage starting in 2026.

This new policy, combined with the rollout of Medicare's drug price negotiations, marks a significant shift in federal prescription drug oversight and highlights the increasing need for expert guidance from financial and insurance advisors.

The Drugs That Launch the Policy

The Centers for Medicare and Medicaid Services released its list of the first set of prescription drugs that will be subject to price negotiations under Medicare Part D, the Medicare prescription drug coverage program.

These medications include Eliquis, Jardiance and Xarelto — widely used to treat conditions like blood clots, heart failure and Type 2 diabetes.

The list also features expensive cancer drugs and treatments for chronic kidney disease.

According to CMS, these drugs represent some of the highest total spending under Medicare Part D.

Starting Jan. 1, the new prices will apply to Medicare enrollees who use these therapies, potentially lowering monthly costs by hundreds of dollars for some.

But the degree of savings depends on how individual Part D or Medicare Advantage plans adjust. Differences in cost-sharing, tier placement and prior authorization requirements could all affect how much a beneficiary ultimately pays.

That's where an advisor's insight becomes essential.

Weight-Loss Drugs Enter the Fold

On Nov. 6, the White House announced a separate deal with Novo Nordisk and Eli Lilly to slash the prices of their GLP-1 class weight-loss drugs, including Wegovy and Zepbound, for Medicare and Medicaid programs.

Under the agreement, the government will pay between $149 and $245 per month for the drugs, while eligible Medicare patients may pay around $50 monthly out of pocket.

For the first time, Medicare will also extend coverage of these medications for obesity treatment, not just diabetes, provided that certain clinical criteria are met.

These moves signal a major expansion of what's considered "medically necessary" care under Medicare.

They raise fresh questions about access, eligibility and coverage changes.

Many beneficiaries are likely to need help navigating the clinical guidelines and cost implications.

What Clients Need to Know About Their Coverage

These policy shifts set the stage for major changes in how plans are structured and how clients will experience Medicare coverage in 2026.

Here are some of the factors advisors should track:

Premium adjustments: While lower drug prices may help stabilize premiums, plans may shift benefits or cost structures to absorb changes.

Formulary movement: Some drugs may change tiers or carry new restrictions, such as prior authorizations or step therapy rules.

Access and eligibility: For weight-loss medications, beneficiaries must meet specific body mass index thresholds and health conditions.

Without guidance, they could miss new coverage opportunities or face unexpected denials.

Importantly, plan options will vary widely across regions and insurers.

The right coverage choice for one client could be the wrong fit for another.

This makes individual plan reviews and side-by-side comparisons more important than ever.

How Advisors Can Lead Clients Through Change

The shift coming in 2026 will change how many beneficiaries experience Medicare drug coverage.

For advisors, the opportunity lies in helping clients understand what these changes mean for them and staying engaged as the program continues to evolve.

1. Shifting drug profiles and real client impact.

When the first set of negotiated drugs takes effect, many clients will see familiar names on that list.

Understanding who may be affected and how their costs could change gives advisors an opening for meaningful conversations.

Reviewing medication lists, noting which drugs are included in the negotiation, and tracking potential cost differences can help bring clarity to clients who are trying to plan ahead.

This type of awareness transforms a complex policy shift into something tangible and personal.

2. A pivotal enrollment season with higher stakes.

The 2025 Medicare annual enrollment period carries more weight than usual as Medicare plans adjust ahead of 2026.

Plan formularies, preferred pharmacies, and prior authorization rules are all likely to shift.

Advisors who pay attention can help clients make informed choices.

Staying alert to emerging trends allows advisors to simplify what could otherwise be an overwhelming enrollment season.

3. A long-term shift that continues to expand.

Medicare's drug price negotiations are designed to grow each year and, eventually, will include certain Part B medications.

That makes this an ongoing transformation rather than a single milestone.

Advisors who stay visible and keep communication consistent become the people clients naturally turn to for context and reassurance.

Over time, that steady engagement builds trust and reinforces the advisor's role as a reliable guide through an evolving healthcare landscape.

Advisors are uniquely positioned to guide clients through this change.

By helping them understand the fine print, make smart choices, and access benefits they may not even realize are available, advisors transform complexity into clarity and uncertainty into confidence.

With policy in motion and plan offerings evolving, one thing is certain: Medicare clients need expert guidance more than ever.

And for advisors, that's an opportunity to deliver the kind of service that sets them apart.

Tricia Blazier, J.D., is director of Healthcare Insurance Services at Allsup.

Credit: Aamir/Adobe Stock